Clinical Trials on Bichat's Fat Pad Atrophy in Czechia
Total 15 results
-
University Hospital OlomoucNot yet recruiting
-
Baxalta now part of ShireBaxalta Innovations GmbH, now part of ShireCompletedPrimary Immunodeficiency Diseases (PID)Denmark, United Kingdom, Czechia, France, Greece, Hungary, Slovakia, Sweden
-
Wave Life Sciences Ltd.TerminatedDuchenne Muscular DystrophyUnited States, Belgium, United Kingdom, Czechia, Canada, France, Italy, Sweden
-
NS Pharma, Inc.Nippon Shinyaku Co., Ltd.Active, not recruitingDuchenne Muscular DystrophyKorea, Republic of, Chile, Japan, China, United Kingdom, Netherlands, Spain, Norway, Russian Federation, Australia, Greece, Italy, New Zealand, Turkey, Mexico, Czechia, Canada
-
ReveraGen BioPharma, Inc.University of Pittsburgh; Newcastle University; European Union; Cooperative International...CompletedDuchenne Muscular DystrophyUnited States, Belgium, Canada, United Kingdom, Spain, Netherlands, Sweden, Czechia, Australia, Greece, Israel
-
BioMarin PharmaceuticalNo longer availableDuchenne Muscular DystrophyUnited States, Germany, United Kingdom, Japan, Netherlands, France, Spain, Korea, Republic of, Italy, Belgium, Taiwan, Argentina, Australia, Bulgaria, Czechia, Israel, Norway, Poland, Russian Federation, Turkey
-
PTC TherapeuticsCooperative International Neuromuscular Research Group; The John Walton Muscular...Active, not recruitingMuscular Dystrophy, DuchenneGermany, France, United Kingdom, Brazil, Italy, Austria, Sweden, Czechia, Greece, Hungary, Israel, Latvia, Norway, Portugal, Romania, Slovenia
-
Sarepta Therapeutics, Inc.Active, not recruitingMuscular Dystrophy, DuchenneUnited States, Korea, Republic of, India, Slovenia, Turkey, United Kingdom, Germany, Switzerland, Spain, Czechia, France, Serbia, Taiwan, Netherlands, Mexico, Colombia, Denmark, New Zealand, Norway, Greece, Hungary, Ireland, Italy, Jo... and more
-
FibroGenTerminatedDuchenne Muscular DystrophyUnited States, Belgium, Israel, Spain, Canada, Australia, Switzerland, United Kingdom, France, China, Netherlands, Italy, Austria, Czechia
-
Sarepta Therapeutics, Inc.TerminatedAn Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular DystrophyDuchenne Muscular DystrophyUnited States, Belgium, Canada, Spain, United Kingdom, Czechia, Germany, Israel, Bulgaria, France, Italy, Poland, Sweden
-
GlaxoSmithKlineCompletedMuscular DystrophiesFrance, Denmark, Germany, Belgium, Spain, Turkey, Korea, Republic of, Brazil, Netherlands, Italy, Chile, Japan, Canada, Hungary, Russian Federation, Czechia, Poland, Norway, Argentina, Taiwan
-
Sarepta Therapeutics, Inc.Active, not recruitingDuchenne Muscular DystrophyUnited States, Korea, Republic of, Italy, United Kingdom, Canada, Poland, Spain, France, Germany, Belgium, Australia, Czechia, Serbia, Greece, Argentina, Bulgaria, Denmark, Hungary, India, Ireland, Israel, Mexico, Russian Federation, ...
-
PTC TherapeuticsCompletedNervous System Diseases | Genetic Diseases, Inborn | Genetic Diseases, X-Linked | Musculoskeletal Diseases | Muscular Diseases | Neuromuscular Diseases | Muscular Dystrophies | Muscular Disorders, Atrophic | Muscular Dystrophy, DuchenneUnited States, Spain, Korea, Republic of, Belgium, France, Canada, Australia, United Kingdom, Israel, Italy, Brazil, Chile, Czechia, Sweden, Switzerland, Turkey, Germany, Poland
-
PTC TherapeuticsTerminatedNervous System Diseases | Genetic Diseases, Inborn | Genetic Diseases, X-Linked | Musculoskeletal Diseases | Muscular Diseases | Neuromuscular Diseases | Muscular Dystrophies | Muscular Disorders, Atrophic | Muscular Dystrophy, DuchenneUnited States, Spain, Korea, Republic of, Belgium, France, Canada, Australia, United Kingdom, Israel, Italy, Germany, Brazil, Bulgaria, Chile, Czechia, Poland, Sweden, Switzerland, Turkey
-
GlaxoSmithKlineTerminatedMuscular DystrophiesFrance, Bulgaria, Denmark, Germany, Belgium, Canada, Spain, Turkey, United Kingdom, Korea, Republic of, Brazil, Netherlands, Italy, Japan, Czech Republic, Chile, Israel, Hungary, Russian Federation, Australia, Poland, Norway, Argentina and more